Compare FBIZ & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FBIZ | BBNX |
|---|---|---|
| Founded | 1909 | 2015 |
| Country | United States | United States |
| Employees | N/A | 423 |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 488.9M | 493.1M |
| IPO Year | 2012 | N/A |
| Metric | FBIZ | BBNX |
|---|---|---|
| Price | $55.74 | $11.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $65.00 | $23.80 |
| AVG Volume (30 Days) | 40.3K | ★ 1.2M |
| Earning Date | 04-23-2026 | 04-21-2026 |
| Dividend Yield | ★ 2.37% | N/A |
| EPS Growth | ★ 14.23 | N/A |
| EPS | ★ 5.94 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.69 | $34.90 |
| Revenue Next Year | $8.47 | $34.63 |
| P/E Ratio | $9.67 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $45.90 | $8.80 |
| 52 Week High | $60.54 | $32.71 |
| Indicator | FBIZ | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 46.02 | 48.95 |
| Support Level | $53.56 | $11.33 |
| Resistance Level | $59.76 | $11.92 |
| Average True Range (ATR) | 1.36 | 1.12 |
| MACD | -0.20 | 0.17 |
| Stochastic Oscillator | 20.26 | 56.26 |
First Business Financial Services Inc operates as a bank holding company. The Bank operates as a business bank, delivering a full line of commercial banking products, including commercial loans and commercial real estate loans, to meet the specific needs of small and medium-sized businesses, business owners, executives, professionals, and high-net-worth individuals. The company's products and services include commercial lending, SBA lending and servicing, asset-based lending, equipment financing, factoring, trust, and investment services, treasury management services, and a broad range of deposit products. Geographically, all the business activity functioned through the region of the United States.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.